XML 100 R74.htm IDEA: XBRL DOCUMENT v3.24.0.1
Acquisitions - Summary of Assets and Liabilities Acquired (Details) - USD ($)
$ in Millions
2 Months Ended 12 Months Ended
Sep. 30, 2022
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Jul. 19, 2022
Intangible assets          
Goodwill   $ 1,593.6 $ 1,589.3 $ 1,463.3  
Fair Value of Liabilities Assumed          
Cash purchase price, net of acquired cash [1]   $ 16.5 $ 198.2 $ 5.2  
Developed Technology          
Fair Value of Liabilities Assumed          
Weighted avg. useful life remaining at December 31, 2023   12 years      
BioPhero          
Fair Value of Assets Acquired          
Cash         $ 10.0
Intangible assets          
Goodwill         130.7
Other Assets         3.4
Total Assets         220.9
Fair Value of Liabilities Assumed          
Deferred income tax liabilities         16.6
Other Liabilities         1.1
Total Liabilities         17.7
Net Assets         203.2
Cash purchase price, net of acquired cash $ 193.2        
BioPhero | Developed Technology          
Intangible assets          
Business combination, recognized identifiable assets acquired and liabilities assumed, intangible assets, other than goodwill         $ 66.3
Fair Value of Liabilities Assumed          
Weighted avg. useful life remaining at December 31, 2023         15 years
BioPhero | In-process research & development          
Intangible assets          
Business combination, recognized identifiable assets acquired and liabilities assumed, intangible assets, other than goodwill         $ 10.5
[1] The acquisitions, including cost and equity method, net amount in 2023 includes an $11.9 million payment related to the in-process research and development assets acquired. For additional detail on this transaction, see Note 8 to our consolidated financial statements included within this Form 10-K. The 2022 activity includes the purchase price of Biophero of approximately $193 million. For additional detail on this transaction, see Note 4 to our consolidated financial statements included within this Form 10-K.